comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 00:39:11 - browse：31567

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Neurocrine congenital adrenal hyperplasia trial succeeds

WSS

People with substance use disorder deserve online privacy

ASCO eve: Let’s set the table for this year's meeting

The struggle to figure out which patients 'deserve' Wegovy

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Information blocking fines are now fair game in health care

Free Covid tests will again be offered to all U.S. households

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Moonlake's readout produced a cash windfall. Risks remain

Assistant physicians can help address the primary care shortage

Medical leaders decry Supreme Court decision on affirmative action

The unintended consequences of overturning Roe v. Wade

Walensky prepares to leave CDC — and Congress — behind

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

How one medical school became remarkably diverse

Senate bill would ban some hospital facility fees

DIEP, the 'gold standard' of breast reconstruction, is under threat

Addressing health care workers' trauma can help fight burnout

focus

Investigation reveals sickle cell patients pressured into sterilizations

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Scrutiny of post

Covid’s new normal has set in amid another rise in cases

UnitedHealth argues against case alleging wrongful AI care denials

hotspot

knowledge

focus

Wikipedia